Wells Fargo & Company Kal Vista Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 20,165 shares of KALV stock, worth $196,407. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,165
Previous 15,622
29.08%
Holding current value
$196,407
Previous $180,000
5.56%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding KALV
# of Institutions
130Shares Held
53.3MCall Options Held
63.5KPut Options Held
36.6K-
Vr Adviser, LLC New York, NY6.25MShares$60.9 Million8.73% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.91MShares$47.9 Million1.73% of portfolio
-
Tang Capital Management LLC San Diego, CA4.89MShares$47.7 Million3.11% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.89MShares$47.6 Million2.48% of portfolio
-
Vestal Point Capital, LP New York, NY4.77MShares$46.5 Million2.4% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $240M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...